![]() |
|
|||||||||||
|
![]() |
|
||||||||||
|
Adventures in Translational Research: A Model for Bench to Bedside Breakthroughs CHORI-Based Technology Poised for Widespread Clinical Use through Quest Laboratories
By no means an overnight discovery, the Ion Mobility Analysis is built upon many years of research by CHORI Senior Scientist Ronald Krauss, MD, who, with his colleagues at CHORI and Lawrence Berkeley National Laboratory, pioneered the new Ion Mobility Analysis. While Dr. Krauss and his colleagues had been utilizing a variety of techniques with which to measure various types of lipoproteins, none of them had all the necessary ingredients that they were seeking. “What one would ideally like is a method that can measure all the different types of particles accurately and precisely, but that could also, ultimately, be performed by a clinical lab,”explains Dr. Krauss. With the Ion Mobility Analysis, first discovered by Dr. Krauss and his colleagues 5 years ago, however, the perfect recipe for success came together. Utilizing a very sophisticated technology that relies on velocity to separate and count lipoproteins by weight and size, the test produces a complete lipoprotein profile based on the direct physical separation of the particles. “The test produces a profile based on the number of lipoprotein particles in all of the major categories that we feel are important in heart disease risk assessment,” Dr. Krauss says. While standard measurements which provide levels of cholesterol contained in LDL and HDL as a whole,give essential information at relatively low cost, the Ion Mobility Analysis expands upon that data to offer a more complete picture.
As Dr. Krauss says, “What you want in translational medicine is to be able to take basic science from the lab that initially may not have a clear clinical application and see where that information might have clinical value.” The ultimate goal, of course, is to then determine how the information could best be translated into something that could be delivered to patients, and could improve the overall health of the population. “That’s really what we’re trying to do with research, to bring into practice ways that could improve health on the widest scale possible.” With heart disease the leading cause of death in the United States, and cholesterol measurement providing a key component of any preventative defense, the Ion Mobility Analysis provides just that potential - to improve the prevention and treatment of heart disease on a global scale. Back |
||||||||||||
|
© 2005 Children's Hospital Oakland Research Institute |
||||||||||||